Retraction Watch reported on 17 November 2026 that Eliezer Masliah, the former director of neuroscience at the US National Institute on Aging (NIA), now has 32 retractions, 15 of them issued in 2026, as journals continue to review his work after misconduct allegations and findings. For research offices and integrity officers, the case shows how a single researcher’s record can be corrected over years, one journal notice at a time.
What happened
According to Retraction Watch, investigations into Masliah’s work have left him with 32 retractions to date, with 15 of them coming this year. The outlet says nearly three dozen of the articles named in a 2024 dossier have now been retracted, covering work published from 2008 to 2022.
Two of the recent notices are public on the publishers’ sites. The Nature Communications notice was published on 5 October 2026 and retracts a paper first published on 27 August 2018, on LRRK2 kinase and alpha-synuclein propagation. The Cell Death & Disease notice was published on 6 November 2026 and retracts a paper first published on 10 February 2011, on CDK5 signalling and neurogenesis in models of Alzheimer’s disease.
What the retraction notices say
The Nature Communications retraction note says concerns were raised after publication about the figures. It lists three specific problems: the Fig. 7a N2 image appears highly similar to an image in an earlier paper; the Fig. 8f images for two conditions appear to overlap; and the Fig. 9d images for two conditions appear to overlap. It adds that further checks by the publisher found some highly similar patterns and other irregularities in the images in Fig. 8.
The same note records the authors’ position. They stated that the quantitative analyses reported in the article were derived from the complete image datasets rather than the representative panels displayed, and that the underlying source data are retained. The authors nonetheless accept that the integrity of the figures as published cannot be assured, and the note states that all living authors agree to the retraction. One author, Edward Rockenstein, is deceased. The editorial record also shows an editor’s note dated 24 July 2026 alerting readers to concerns about the reliability of the data, which preceded the retraction.
The Cell Death & Disease retraction note says the editors retracted the paper after concerns about the figures and supplementary materials. It cites a merged image in Fig. 4 that does not fully match its two component channels and appears to contain a duplicated pattern, Fig. 8 panels that appear to overlap, and Fig. S4 panels with highly similar artifacts at different brightness. The note concludes that the editors no longer have confidence in the presented data. It states that two authors, L. Crews and E. Masliah, do not agree with the retraction.
Key details
| Item | As stated by the source |
|---|---|
| Retractions to date | 32, with 15 in 2026 (Retraction Watch, 17 November 2026) |
| Papers in the 2024 dossier | 132, in a dossier of about 300 pages (Retraction Watch) |
| Nature Communications notice | 5 October 2026, for a paper published 27 August 2018 |
| Cell Death & Disease notice | 6 November 2026, for a paper published 10 February 2011 |
| Masliah’s role at NIA | Director of neuroscience, 2016 to 2024, overseeing a research portfolio worth nearly $2.6 billion a year (Retraction Watch) |
| Scale of his record | More than 800 coauthored papers, cited over 147,000 times according to Clarivate’s Web of Science (Retraction Watch) |
Background: the NIH findings and the 2024 investigation
Retraction Watch says Masliah worked as a professor at the University of California, San Diego before joining NIA, and that much of his career focused on alpha-synuclein, a protein central to Parkinson’s disease research. In September 2024 the National Institutes of Health announced the result of its own misconduct inquiry. As MDedge reported, NIH said the investigation found ‘falsification and/or fabrication involving reuse and relabel of figure panels representing different experimental results in two publications.’ NIH said it would notify the two journals so that appropriate action could be taken, and that Masliah was no longer serving as director of NIA’s Division of Neuroscience.
The Associated Press account of the same statement says NIH described the findings as involving images in two studies co-authored by Masliah, with figure panels representing different experimental results reused or relabeled. MDedge adds that the inquiry reportedly followed allegations from the US Department of Health and Human Services’ Office of Research Integrity, that the investigation phase ran from December 2023 to 15 September 2024, and that NIH said allegations about his extramural work before joining NIH would be referred to that office.
The NIH statement came the same day that Science published an investigation by Charles Piller. MDedge’s summary of it says a neuroscientist and forensic image analysts produced a 300-page dossier of suspect images across 132 papers published between 1997 and 2023, and concluded that the pattern raised a credible concern for research misconduct. Retraction Watch names the analysts as Matthew Schrag of Vanderbilt University, Mu Yang of Columbia University, Kevin Patrick and Elizabeth Bik.
Reaction
Seung-Jae Lee, the corresponding author of the Nature Communications paper and a professor at Seoul National University, told Retraction Watch that the journal first contacted him in 2024 over concerns raised on PubPeer, and that his group supplied the original images and raw data it had. He said he takes responsibility for the integrity of the work from his own laboratory and regrets the errors in the published figures, adding that he does not believe the errors undermine the paper’s central claim.
Schrag told Retraction Watch the team saw images reused in different contexts, changed channel intensities and altered features within images, and that irregularities ran through the portfolio from the late 1990s. He said Masliah has issued a large number of corrections, some of which introduced further problems. Piller told the outlet he expects more retractions as time goes by ‘because the number of papers is so huge.’
What it means for researchers, universities and research offices
For researchers in neurodegeneration, the practical issue is citation. Retraction Watch notes that some of Masliah’s work was later cited in studies examining possible treatments for neurodegenerative disease, including Cerebrolysin, a peptide mixture used in some countries that is not approved by the US Food and Drug Administration. A retraction removes a paper from the reliable literature, but papers that cite it, and reviews that pooled its results, are not corrected automatically. Authors of reviews and meta-analyses that include Masliah-coauthored papers have reason to re-check their inclusion lists against the retraction record.
For universities and research offices, the case shows that findings of research misconduct and journal action run on separate tracks. NIH’s finding concerned two publications; the journals’ notices, issued across 2026, rest on image concerns assessed paper by paper, and in the Cell Death & Disease case some listed authors dispute the outcome. Offices that handle the Office of Research Integrity process or institutional inquiries should expect co-authors and former colleagues to receive publisher correspondence long after an institutional case closes, and may wish to keep raw image files and source data retained under their data policies. The Nature Communications authors’ statement that source data are retained, and Lee’s account of supplying original images, show why retention matters when a publisher asks.
The notices also illustrate how image manipulation concerns are raised and checked. In the Nature Communications case the concerns were posted publicly on PubPeer, then followed by an editor’s note, further publisher checks and a retraction. Journals and integrity offices can use the specific panel-level descriptions in the notices as a model for how a retraction states its grounds.
What happens next
Retraction Watch says journals continue to examine Masliah’s work, and Piller told the outlet he anticipates further retractions. Retraction Watch maintains a searchable database of retractions where each new notice for this author can be tracked as it appears. Each journal’s notice, once published, becomes the authoritative record for its paper.
Sources
- Retraction Watch, ‘Former NIH neuroscientist passes 30 retractions’, 17 November 2026: retractionwatch.com
- Nature Communications, ‘Retraction Note: LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation’, 5 October 2026: nature.com
- Cell Death & Disease, ‘Retraction Note: Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer’s disease’, 6 November 2026: nature.com
- MDedge Neurology, ‘Prominent NIH Neuroscientist Fired Over Alleged Research Misconduct’, 30 September 2024: mdedge.com
- The Associated Press, ‘A top government scientist engaged in research misconduct, NIH finds’, September 2024: infonews.ca







